Anti-PD-1/PD-L1 antibodies versus docetaxel in patients with previously treated non-small-cell lung cancer

Anti-PD-1/PD-L1 antibodies have been proved one of the most promising treatments against non-small cell lung cancer (NSCLC); however, whether anti-PD-1/PD-L1 antibodies can provide added benefits for pretreated patients with advanced NSCLC and which patients are most likely to benefit from anti-PD-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Qi, Xie, Mixue, He, Mengye, Yan, Feifei, Zhang, Xiaochen, Yu, Sufen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Meta-Analysis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800935/
https://www.ncbi.nlm.nih.gov/pubmed/29484143
http://dx.doi.org/10.18632/oncotarget.23584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5800935/
https://www.ncbi.nlm.nih.gov/pubmed/29484143
http://dx.doi.org/10.18632/oncotarget.23584

Ejemplares similares